

CORRECTION


Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- β RI inhibitor galunisertib

The *PLOS ONE* Staff

The Data Availability statement for this paper is incorrect. The publisher apologizes for the error. The correct statement is: Data are available upon request at vivli.org. Access to the data is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org. In your request, please include the following accession/reference numbers so that we can identify the dataset you're trying to access: NCT01246986.

Reference

1. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. (2020) Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- β RI inhibitor galunisertib. *PLoS ONE* 15(3): e0222259. <https://doi.org/10.1371/journal.pone.0222259> PMID: [32210440](https://pubmed.ncbi.nlm.nih.gov/32210440/)



OPEN ACCESS

Citation: The *PLOS ONE* Staff (2020) Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- β RI inhibitor galunisertib. *PLoS ONE* 15(6): e0235580. <https://doi.org/10.1371/journal.pone.0235580>

Published: June 25, 2020

Copyright: © 2020 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.